



22 July 2021

Reach - non-regulatory announcement

Nuformix plc
(“Nuformix” or the “Company”)

Letter to shareholders re: Dr Anne Brindley

Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, announces that further to the RNS issued yesterday on the departure of Dr Anne Brindley as CEO, the Company has issued a letter to shareholders. The letter can be viewed here: <https://nuformix.com/document-center/>

Enquiries:

Nuformix plc

Dr Alastair Riddell, Non-Executive Chairman
Dr Anne Brindley, CEO

via Walbrook

Allenby Capital Limited

Nick Athanas / George Payne (Corporate Finance)
Stefano Aquilino / Matt Butlin (Sales and Corporate Broking)

+44 (0) 20 3328 5656

Walbrook PR

Anna Dunphy / Paul McManus / Kiki Zaccagnini

nuformix@walbrookpr.com or +44 (0)20 7933 8780

Tel: +44 (0)7876 741 001 / +44 (0)7980 541 893

About Nuformix

Nuformix is a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing. The Company aims to use its expertise in discovering, developing and patenting novel drug forms, with improved physical properties, to develop new products in new indications that are, importantly, differentiated from the original (by way of dosage, delivery route or presentation), thus creating new and attractive commercial opportunities. Nuformix has an early-stage pipeline of preclinical and Phase 1-ready assets with potential for significant value and early licensing opportunities.

For more information, please visit www.nuformix.com.